Holen Sie sich die Stockscreener-App
5.14
1.97%
0.12
Handel nachbörslich:
5.05
-0.09
-1.75%
Schlusskurs vom Vortag:
$5.02
Offen:
$5.02
24-Stunden-Volumen:
690.15K
Relative Volume:
0.46
Marktkapitalisierung:
$1.05B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-118.84M
KGV:
-9.6183
EPS:
-0.5344
Netto-Cashflow:
$-101.06M
1W Leistung:
+8.45%
1M Leistung:
-0.02%
6M Leistung:
-4.50%
1J Leistung:
+80.24%
1-Tages-Spanne:
$4.97
$5.14
1-Wochen-Bereich:
$4.72
$5.19
52-Wochen-Spanne:
$1.89
$7.005
Savara Inc Stock (SVRA) Company Profile
Firmenname
Savara Inc
Sektor
Branche
Telefon
51285113796
Adresse
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.14 | 1.03B | 0 | -118.84M | -101.06M | -0.5344 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-13 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-11-07 | Eingeleitet | Guggenheim | Buy |
| 2023-05-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-31 | Herabstufung | Jefferies | Buy → Hold |
| 2021-03-16 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-15 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-13 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | Fortgesetzt | ROTH Capital | Neutral |
| 2018-01-03 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-09-27 | Fortgesetzt | ROTH Capital | Buy |
| 2017-09-22 | Eingeleitet | Jefferies | Buy |
| 2017-09-11 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Savara Inc Aktie (SVRA) Neueste Nachrichten
New aPAP Phase 3 Data and Wider Losses Might Change The Case For Investing In Savara (SVRA) - simplywall.st
Savara Inc. (SVRA) Reports Q1 Financial Results - Insider Monkey
SVRA Stock Price, Quote & Chart | SAVARA INC (NASDAQ:SVRA) - ChartMill
Savara Inc stock (US80633A1025): fresh IMPALA?2 data at ATS 2026 keeps rare?disease bet in focus - AD HOC NEWS
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 20 - BioSpace
Savara presents biomarker data from molgramostim trial at ATS - Investing.com
Savara (SVRA) Reports New Clinical Findings at ATS 2026 Conferen - GuruFocus
Savara presents biomarker data from molgramostim trial at ATS By Investing.com - Investing.com Australia
Rare lung disease trial: Savara drug cuts biomarkers tied to severity - Stock Titan
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - BioSpace
Savara presents 48-week data on molgramostim for rare lung disease By Investing.com - Investing.com South Africa
Savara presents 48-week data on molgramostim for rare lung disease - Investing.com Nigeria
SVRA: MOLBREEVI nears approval for aPAP, backed by strong data and robust commercial preparation - TradingView
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - BioSpace
Savara Inc stock (US80633A1025): higher losses, trial progress and elevated short interest - AD HOC NEWS
Savara reports exercise improvements in aPAP drug trial By Investing.com - Investing.com South Africa
Savara reports exercise improvements in aPAP drug trial - Investing.com
Is Savara’s Rising Quarterly Loss Reshaping the Risk‑Reward Profile for Investors in SVRA? - simplywall.st
Savara Inc stock (US80633A1025): respiratory disease specialist after latest clinical and funding up - AD HOC NEWS
SVRA Stock Slips Post-Market After FDA Delays Decision On Pulmonary Therapy - Stocktwits
Guggenheim Reaffirms Their Buy Rating on Savara (SVRA) - The Globe and Mail
Savara stock (US80633A1025): Rare disease biotech gains 3.74% on trading momentum - AD HOC NEWS
A Quick Look at Today's Ratings for Savara(SVRA.US), With a Forecast Between $9 to $16 - Moomoo
Savara Reports First Quarter Financial Results and Provides Business Update - BioSpace
SVRA SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
Savara (SVRA) Prepares for Commercial Launch with Strong Financi - GuruFocus
SVRA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TradingKey - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
Savara Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings Flash (SVRA) Savara Posts Q1 Per Share Loss $-0.15, vs. FactSet Est of $-0.13 Loss - marketscreener.com
Earnings Flash (SVRA) Savara Posts Q1 Per Share Loss $-0.15, Vs. FactSet Est of $-0.13 Loss - Moomoo
Savara Q1 net loss widens on higher R&D costs - TradingView
Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Savara (SVRA) deepens Q1 2026 loss while pushing MOLBREEVI toward key FDA and EMA decisions - Stock Titan
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference - BioSpace
Swedbank AB Has $5.13 Million Position in Savara Inc. $SVRA - MarketBeat
Nan Fung Trinity HK Ltd. Takes $10.18 Million Position in Savara Inc. $SVRA - MarketBeat
Savara Inc. $SVRA Position Boosted by F m Investments LLC - MarketBeat
SVRA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Number of shareholders of Savara, Inc. – NASDAQ:SVRA - TradingView
MSN Money - MSN
Savara faces earnings test ahead of crucial FDA decision By Investing.com - Investing.com South Africa
Savara faces earnings test ahead of crucial FDA decision - Investing.com
Savara (SVRA) to Release Earnings on Tuesday - MarketBeat
Finanzdaten der Savara Inc-Aktie (SVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Savara Inc-Aktie (SVRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| McCracken Joseph S | Director |
Feb 16 '26 |
Option Exercise |
1.76 |
1,807 |
3,180 |
302,644 |
| RAMSAY DAVID A | Director |
Dec 19 '25 |
Sale |
6.06 |
20,000 |
121,220 |
2,533,642 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):